Tenofovir alafenamide hemifumarate(CAS: 1392275-56-7)

Tenofovir alafenamide hemifumarate (CAS: 1392275-56-7) is an antiretroviral medication used to treat HIV infections. It is a prodrug form of tenofovir, designed to improve bioavailability and reduce systemic toxicity. The compound has a molecular formula of C14H21N6O15P and is characterized by its stability in solid form, solubility in water, and role as a nucleotide reverse transcriptase inhibitor (NRTI) in pharmaceutical applications.

Tenofovir alafenamide hemifumarate (CAS: 1392275-56-7) is primarily used in the pharmaceutical industry for HIV treatment, as part of combination antiretroviral therapy (ART). It is also employed in research for studying antiviral mechanisms and drug development. Its high solubility and improved pharmacokinetic profile make it a key compound in combating HIV and related viral infections.

Tenofovir alafenamide hemifumarate (CAS: 1392275-56-7) is considered safe when used as directed in medical treatments. It has low toxicity compared to other NRTIs and is generally well-tolerated. However, handling precautions include avoiding direct contact with skin or eyes, using protective gloves, and following standard lab safety protocols. Safety standards ensure its proper use in pharmaceutical applications and compliance with regulatory guidelines.

Tenofovir alafenamide hemifumarate (CAS: 1392275-56-7) should be stored in a cool, dry place at 2-8°C, protected from light. It requires airtight containers to maintain stability and prevent moisture exposure. Proper storage ensures optimal shelf life and preserves its pharmaceutical efficacy, as recommended by manufacturers and safety standards.